Beraprost sodium cas 88475-69-8

Beraprost is an analog of prostacyclin in which the unstable enol-ether has been replaced by a benzofuran ether function. This modification increases the plasma half-life from 30 seconds to several hours, and permits the compound to be taken orally. Doses of 20-100 µg in humans, given 1 to 3 times per day, have been demonstrated to improve clinical end points in diseases responsive to prostacyclin. Oral beraprost therapy improved the survival and pulmonary hemodynamics of patients with primary pulmonary hypertension.1 Beraprost inhibits platelet aggregation in healthy subjects and in diabetic patients at similar doses.2,3

Beraprost sodium is a potent IP receptor agonist, inhibiting ADP-induced platelet aggregation and P-selectin expression.

Related Prodcuts:

Latanoprost Lactol; trans-(15S)-Latanoprost; Latanoprostene bunod; 15(S)-Latanoprost; trans-Latanoprost; (+)-Cloprostenol; Cloprostenol; Misoprostol; Tafluprost; Dinoprostone; Dinoprost; Trometamol; Alprostadil; Bimatoprost; (+/-)-Corey lactone diol; Limaprost Alfadex N-2; Dehydrate limaprost; Carboprost tromethamine

1. Nagaya, N.,Uematsu, M.,Okano, Y., et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. Journal of the American College of Cardiology 34, 1188-1192 (1999).

2. Nony, P.,Ffrench, P.,Girard, P., et al. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: A study in healthy male subjects. Canadian Journal of Physiology and Pharmacology 74, 887-893 (1996).

3. Kato, H.,Takashima, T.,Kishikawa, H., et al. Effect of beraprost sodium, a stable prostaglandin I2 analogue, on platelet aggregation in diabetes mellitus. International Journal of Clinical Pharmacology Research 16, 99-102 (1996).